beta
/2383O A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281
Abstract

Abstract N/A

RelatedView All
CitationsView All
Citing-
Cited By-